Drug reference

Artenimol with piperaquine phosphate

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 672, 673

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Treatment of uncomplicated falciparum malaria ▶BY MOUTH ▶Child 6 months–17 years (body-weight 7–12 kg): 0.5 tablet once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after ﬁrst course ▶Child 6 months–17 years (body-weight 13–23 kg): 1 tablet once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after ﬁrst course ▶Child 6 months–17 years (body-weight 24–35 kg): 2 tablets once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after ﬁrst course ▶Child 6 months–17 years (body-weight 36–74 kg): 3 tablets once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after ﬁrst course ▶Child 6 months–17 years (body-weight 75–99 kg): 4 tablets once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after ﬁrst course ▶Adult (body-weight 36–74 kg): 3 tablets once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after ﬁrst course ▶Adult (body-weight 75–99 kg): 4 tablets once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after ﬁrst course

PDF page 672

Contra Indications

Acute myocardial infarction. bradycardia. congenital long QT syndrome. electrolyte disturbances. family history of sudden death. heart failure with reduced left ventricular ejection fraction. history of symptomatic arrhythmias. left ventricular hypertrophy. risk factors for QT interval prolongation. severe hypertension

PDF page 672

Safety

Interactions

→Appendix 1: antimalarials

PDF page 672

Side Effects

▶Common or very common Anaemia. arrhythmias (in adults) . asthenia. conjunctivitis (in children). eosinophilia. fever . headache (uncommon in children). leucocytosis (in children). leucopenia (in children). neutropenia (in children). QT interval prolongation. thrombocytopenia (in children) ▶Uncommon Abdominal pain (very common in children). appetite decreased (very common in children). arthralgia. cardiac conduction disorder. cough (very common in children). diarrhoea (very common in children). dizziness (in adults). epistaxis (in children). hepatic disorders. hypochromia (in children). increased risk of infection (very common in children). lymphadenopathy (in children). myalgia (in adults). nausea. rhinorrhoea (in children). seizure. skin reactions (very common in children). splenomegaly (in children). stomatitis (in children). thrombocytosis (in children). vomiting (very common in children)

PDF pages 672, 673

Pregnancy

Teratogenic in animal studies—manufacturer advises use only if other antimalarials cannot be used.

PDF page 673

Breast Feeding

Manufacturer advises avoid—present in milk in animal studies.

PDF page 673

Hepatic Impairment

Manufacturer advises caution in jaundice or in moderate to severe failure (no information available)—monitor ECG and plasma potassium concentration. Monitoring Manufacturer advises monitor ECG and plasma-potassium concentration in moderate to severe hepatic impairment.

PDF page 673

Renal Impairment

No information available in moderate to severe impairment. Monitoring Manufacturer advises monitor ECG and plasma-potassium concentration in moderate to severe renal impairment.

PDF page 673

Monitoring Requirements

▶Consider obtaining ECG in all patients before third dose and 4–6 hours after third dose. If QTC interval more than 500 milliseconds, discontinue treatment and monitor ECG for a further 24–48 hours. ▶Obtain ECG as soon as possible after starting treatment then continue monitoring in those taking medicines that increase plasma-piperaquine concentration, in children who are vomiting, in females, or in the elderly.

PDF page 673

Dose and formulations

Directions For Administration

Tablets to be taken at least 3 hours before and at least 3 hours after food. Tablets may be crushed and mixed with water immediately before administration.

PDF page 673

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Tablet ▶Eurartesim (Logixx Pharma Solutions Ltd) Artenimol 40 mg, Piperaquine phosphate 320 mg Eurartesim 320mg/40mg tablets | 12 tablet P £40.00

PDF page 673

Clinical care

Patient And Carer Advice

Patients or carers should be given advice on how to administer tablets containing piperaquine phosphate with artenimol.

PDF page 673

Dose text by age group

Child 6 months–17 years (body-weight 7–12 kg)

0.5 tablet

First-line fragment. Read the complete Indications and Dose section above.

PDF page 672

Child 6 months–17 years (body-weight 13–23 kg)

1 tablet

First-line fragment. Read the complete Indications and Dose section above.

PDF page 672

Child 6 months–17 years (body-weight 24–35 kg)

2 tablets

First-line fragment. Read the complete Indications and Dose section above.

PDF page 672

Child 6 months–17 years (body-weight 36–74 kg)

3 tablets

First-line fragment. Read the complete Indications and Dose section above.

PDF page 672

Child 6 months–17 years (body-weight 75–99 kg)

4 tablets

First-line fragment. Read the complete Indications and Dose section above.

PDF page 672

Adult (body-weight 36–74 kg)

3 tablets once daily for

First-line fragment. Read the complete Indications and Dose section above.

PDF page 672

Adult (body-weight 75–99 kg)

4 tablets once daily for

First-line fragment. Read the complete Indications and Dose section above.

PDF page 672

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Artenimol with piperaquine phosphate

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 672, 673

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF page 672

Contra Indications

PDF page 672

Safety

Interactions

→Appendix 1: antimalarials

PDF page 672

Side Effects

PDF pages 672, 673

Pregnancy

Teratogenic in animal studies—manufacturer advises use only if other antimalarials cannot be used.

PDF page 673

Breast Feeding

Manufacturer advises avoid—present in milk in animal studies.

PDF page 673

Hepatic Impairment

PDF page 673

Renal Impairment

No information available in moderate to severe impairment. Monitoring Manufacturer advises monitor ECG and plasma-potassium concentration in moderate to severe renal impairment.

PDF page 673

Monitoring Requirements

PDF page 673

Dose and formulations

Directions For Administration

Tablets to be taken at least 3 hours before and at least 3 hours after food. Tablets may be crushed and mixed with water immediately before administration.

PDF page 673

Medicinal Forms

PDF page 673

Clinical care

Patient And Carer Advice

Patients or carers should be given advice on how to administer tablets containing piperaquine phosphate with artenimol.

PDF page 673

Dose text by age group

Child 6 months–17 years (body-weight 7–12 kg)

0.5 tablet

First-line fragment. Read the complete Indications and Dose section above.

PDF page 672

Child 6 months–17 years (body-weight 13–23 kg)

1 tablet

First-line fragment. Read the complete Indications and Dose section above.

PDF page 672

Child 6 months–17 years (body-weight 24–35 kg)

2 tablets

First-line fragment. Read the complete Indications and Dose section above.

PDF page 672

Child 6 months–17 years (body-weight 36–74 kg)

3 tablets

First-line fragment. Read the complete Indications and Dose section above.

PDF page 672

Child 6 months–17 years (body-weight 75–99 kg)

4 tablets

First-line fragment. Read the complete Indications and Dose section above.

PDF page 672

Adult (body-weight 36–74 kg)

3 tablets once daily for

First-line fragment. Read the complete Indications and Dose section above.

PDF page 672

Adult (body-weight 75–99 kg)

4 tablets once daily for

First-line fragment. Read the complete Indications and Dose section above.

PDF page 672

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.